Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome
Open Access
- 1 January 2018
- journal article
- research article
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 42 (3) , 207-214
Abstract
Bae KH, et al. Diabetes Metab J. 2018 Jan;42:e6. https://doi.org/10.4093/dmj.2017.0081Keywords
Funding Information
- National Research Foundation of Korea (NRF-2017M3A9G7073086, NRF-2015R1A2A1A10052745)
- Ministry of Health and Welfare (HI16C1501, HI15C0001)
This publication has 17 references indexed in Scilit:
- Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in ApoptosisAntioxidants & Redox Signaling, 2016
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCirculation, 2016
- Prognostic value of PCSK9 levels in patients with acute coronary syndromesEuropean Heart Journal, 2015
- Biomarkers in acute coronary syndromeIJC Metabolic & Endocrine, 2015
- Cross-talk between LOX-1 and PCSK9 in vascular tissuesCardiovascular Research, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- PCSK9Circulation Research, 2014
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJACC, 2012
- Biomarkers in Acute Cardiac DiseaseJACC, 2006